Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May;153(5&6):564-565.
doi: 10.4103/ijmr.ijmr_1092_21.

Interpreting the impact of hydroxychloroquine prophylaxis on SARS-CoV-2 infection

Reetika Malik Yadav  1 , Manisha Rajan Madkaikar  2
Affiliations
Comment

Interpreting the impact of hydroxychloroquine prophylaxis on SARS-CoV-2 infection

Reetika Malik Yadav et al. Indian J Med Res. 2021 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None

Comment in

  • Authors' response.
    Gupta R, Dwivedi T, Gajendra S, Sahoo B, Gupta SK, Vikas H, Singh AR, Mohan A, Bhatnagar S, Singh S, Wundavalli L, Guleria R. Gupta R, et al. Indian J Med Res. 2021 May;153(5&6):565-567. doi: 10.4103/0971-5916.323967. Indian J Med Res. 2021. PMID: 34643565 Free PMC article. No abstract available.

Comment on

References

    1. Gupta R, Dwivedi T, Gajendra S, Sahoo B, Gupta SK, Vikas H, et al. Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers and implications of infection control practice in India. Indian J Med Res. 2021;153:207–13. - PMC - PubMed
    1. Schlagenhauf P, Grobusch MP, Maier JD, Gautret P. Repurposing antimalarials and other drugs for COVID-19. Travel Med Infect Dis. 2020;34:101658. - PMC - PubMed
    1. Bienvenu AL, Marty AM, Jones MK, Picot S. Systematic review of registered trials of hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. One Health. 2020;10:100141. - PMC - PubMed
    1. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: A randomized clinical trial. JAMA Intern Med. 2021;181:195–202. - PMC - PubMed
    1. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020;383:517–25. - PMC - PubMed

Substances